Vertex passes key test in quest to treat kidney diseases

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
BioPharma Dive

Vertex kidney disease drug hits mark in late-stage study

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
pharmaphorum

Vertex preps FDA filing for IgAN drug after phase 3 readout

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Is Vertex Pharmaceuticals Heading to $600?

A new product approval may be right around the corner.
Reuters

Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta ...
sharewise

Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

Vertex Pharmaceuticals Incorporated VRTX stock has declined 4.8% over the past month. This reflects concerns over the ...

Is Vertex Pharmaceuticals (VRTX) Still Fairly Priced After Recent Share Price Weakness

If you are wondering whether Vertex Pharmaceuticals at around US$460 per share still lines up with its fundamentals, you are not alone. This article is here to unpack what that price might imply. The ...